ID: ALA2179835

Max Phase: Preclinical

Molecular Formula: C37H74N18O9

Molecular Weight: 915.12

Molecule Type: Protein

Associated Items:

Representations

Canonical SMILES:  C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)[C@@H](C)O

Standard InChI:  InChI=1S/C37H74N18O9/c1-20(40)28(57)50-22(10-3-5-15-38)29(58)51-24(12-7-17-47-35(41)42)30(59)52-25(13-8-18-48-36(43)44)32(61)55-27(21(2)56)33(62)53-23(11-4-6-16-39)31(60)54-26(34(63)64)14-9-19-49-37(45)46/h20-27,56H,3-19,38-40H2,1-2H3,(H,50,57)(H,51,58)(H,52,59)(H,53,62)(H,54,60)(H,55,61)(H,63,64)(H4,41,42,47)(H4,43,44,48)(H4,45,46,49)/t20-,21+,22-,23-,24-,25-,26-,27-/m0/s1

Standard InChI Key:  QKXIYITZZUBQFY-XTZJLTRESA-N

Associated Targets(Human)

Furin 909 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Subtilisin/kexin type 6 163 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: ProteinTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 915.12Molecular Weight (Monoisotopic): 914.5886AlogP: -6.24#Rotatable Bonds: 34
Polar Surface Area: 495.89Molecular Species: ZWITTERIONHBA: 14HBD: 20
#RO5 Violations: 3HBA (Lipinski): 27HBD (Lipinski): 26#RO5 Violations (Lipinski): 3
CX Acidic pKa: 3.63CX Basic pKa: 11.81CX LogP: -9.48CX LogD: -19.86
Aromatic Rings: 0Heavy Atoms: 64QED Weighted: 0.02Np Likeness Score: 0.28

References

1. Levesque C, Fugère M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, Neugebauer W, Day R..  (2012)  The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.,  55  (23): [PMID:23126600] [10.1021/jm3011178]

Source